Co Diagnostics Ownership

CODX Stock  USD 0.75  0.04  4.94%   
Co Diagnostics secures a total of 31.93 Million outstanding shares. Co Diagnostics owns 6.7 % of its outstanding shares held by insiders and 13.92 % owned by institutions. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
2016-03-31
Previous Quarter
30.1 M
Current Value
30.5 M
Avarage Shares Outstanding
22.4 M
Quarterly Volatility
8.7 M
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as Co Diagnostics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Co Diagnostics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Co Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For more information on how to buy CODX Stock please use our How to Invest in Co Diagnostics guide.

CODX Stock Ownership Analysis

About 14.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.4. Some equities with similar Price to Book (P/B) outperform the market in the long run. Co Diagnostics recorded a loss per share of 1.38. The entity had not issued any dividends in recent years. Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection andor analysis of nucleic acid molecules in the United States and internationally. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Co Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 101 people. For more info on Co Diagnostics please contact Dwight Egan at 801 438 1036 or go to https://www.codiagnostics.com.
Besides selling stocks to institutional investors, Co Diagnostics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Co Diagnostics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Co Diagnostics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Co Diagnostics Quarterly Liabilities And Stockholders Equity

72.38 Million

About 7.0% of Co Diagnostics are currently held by insiders. Unlike Co Diagnostics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Co Diagnostics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Co Diagnostics' insider trades

CODX Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Co Diagnostics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Co Diagnostics backward and forwards among themselves. Co Diagnostics' institutional investor refers to the entity that pools money to purchase Co Diagnostics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Jane Street Group Llc2024-09-30
44.1 K
Thompson Davis & Co Inc2024-09-30
41.5 K
Group One Trading, Lp2024-09-30
40.1 K
Uma Financial Services Inc2024-09-30
28.4 K
Smi Advisory Services Llc2024-09-30
28 K
Citadel Advisors Llc2024-09-30
25.4 K
Morgan Stanley - Brokerage Accounts2024-09-30
14.5 K
Ubs Group Ag2024-09-30
12.8 K
Advisor Group Holdings, Inc.2024-09-30
12.4 K
Vanguard Group Inc2024-09-30
1.8 M
Renaissance Technologies Corp2024-09-30
567.7 K
Note, although Co Diagnostics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Co Diagnostics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Co Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Co Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Co Diagnostics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Co Diagnostics Outstanding Bonds

Co Diagnostics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Co Diagnostics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CODX bonds can be classified according to their maturity, which is the date when Co Diagnostics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for CODX Stock Analysis

When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.